Literature DB >> 18342807

Apoptosis in leukemia: from molecular pathways to targeted therapies.

Aaron D Schimmer1.   

Abstract

Knowledge about apoptosis pathways developed in the last few years is already being translated into novel targeted therapies. Two illustrative approaches to this process are the development of small molecule BCL2 inhibitors and X-linked inhibitors of apoptosis proteins (XIAP) inhibitors. This work demonstrates both the development of new agents based on molecular mechanisms and how these agents further our understanding of the biology of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342807     DOI: 10.1016/j.beha.2007.11.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

1.  Advances in haematological pharmacotherapy in 21st century.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-28       Impact factor: 0.900

2.  Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Authors:  Jennifer Richmond; Alissa Robbins; Kathryn Evans; Dominik Beck; Raushan T Kurmasheva; Catherine A Billups; Hernan Carol; Sue Heatley; Rosemary Sutton; Glenn M Marshall; Deborah White; John Pimanda; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

3.  Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.

Authors:  Mina Fathi; Zahra Amirghofran; Mehdi Shahriari
Journal:  Med Oncol       Date:  2011-04-29       Impact factor: 3.064

4.  Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase.

Authors:  Susmita Mondal; Chandan Mandal; Rajender Sangwan; Sarmila Chandra; Chitra Mandal
Journal:  Mol Cancer       Date:  2010-09-13       Impact factor: 27.401

5.  The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Fatemeh M Kamazani; Gholamreza Bahoush-Mehdiabadi; Mahnaz Aghaeipour; Shahram Vaeli; Zahra Amirghofran
Journal:  Iran J Pediatr       Date:  2014-05-21       Impact factor: 0.364

6.  Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.

Authors:  J Xin; D You; P Breslin; J Li; J Zhang; W Wei; J Cannova; A Volk; R Gutierrez; Y Xiao; A Ni; G Ng; R Schmidt; Z Xia; J Pan; H Chen; M M Patel; P C Kuo; S Nand; A R Kini; J Zhang; J Chen; J Zhu; J Zhang
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

7.  Carbenoxolone induces apoptosis and inhibits survivin and survivin-ΔEx3 genes expression in human leukemia K562 cells.

Authors:  M A Moosavi; S Moasses Ghafary; I Asvadi-Kermani; H Hamzeiy; M Rahmati; A H Ahmadi; A Nikanfar; Z Sanaat; M Asadi-Khiavi
Journal:  Daru       Date:  2011       Impact factor: 3.117

8.  Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.

Authors:  L Steinhart; K Belz; S Fulda
Journal:  Cell Death Dis       Date:  2013-09-12       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.